COO vs PTGX
Cooper Companies (The) vs Protagonist Therapeutics, Inc. — AI-powered side-by-side comparison
COO
Cooper Companies (The)
68
Buy
VS
PTGX
Protagonist Therapeutics, Inc.
69
Buy
| Metric | COO | PTGX |
|---|
| AI Score |
68
|
69
|
| Price |
$73.45
|
$151.71
|
| P/E Ratio |
64.24×
|
127.02×
|
| ROE |
4.6%
|
-21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
64.4%
|
99.9%
|
| Debt / Equity |
0.30×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
54.1
|
61.5
|
| Beta |
0.823
|
1.794
|
| Expected Upside |
+0.1%
|
—
|
AI Committee View
Current Innellis committee reasoning for COO versus PTGX.
PTGX leads by 1 points.
PTGX scores 69/100 (Buy) versus COO at 68/100 (Buy).
COO Committee View
80% agreement
5 analysts
The primary driver is 4 consecutive earnings beats -- consistent execution. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
PTGX Committee View
80% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Weekly RSI at 85 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk